Researchers track Real-World side effects of ofev in lung disease patients
NCT ID NCT04325217
First seen Jan 09, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This study monitors the long-term safety of the drug Ofev in patients with systemic scleroderma-associated interstitial lung disease (SSc-ILD) in Japan. Researchers are tracking side effects, especially stomach issues like diarrhea and nausea, that occur in everyday use. About 586 patients who are new to Ofev will be observed. The goal is to confirm safety findings from earlier clinical trials in a real-world setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG DISEASES, INTERSTITIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, 1416017, Japan
Conditions
Explore the condition pages connected to this study.